Patents by Inventor Marc Capet

Marc Capet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060094732
    Abstract: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.
    Type: Application
    Filed: August 17, 2005
    Publication date: May 4, 2006
    Inventors: Jeffrey Schmitt, Gary Dull, Arielle Genevois-Borella, Marc Capet, Michel Cheve
  • Publication number: 20060089364
    Abstract: The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent.
    Type: Application
    Filed: October 19, 2005
    Publication date: April 27, 2006
    Inventors: Marc Capet, Denis Danvy, Nicolas Levoin, Marcel Morvan, Isabelle Berrebi-Bertrand, Thierry Calmels, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte
  • Patent number: 6887904
    Abstract: Substituted arylcycloalkanes, compositions containing them and use thereof. The present invention relates especially to substituted arylcycloalkanes with therapeutic activity, which may be used such as in oncology.
    Type: Grant
    Filed: December 4, 2002
    Date of Patent: May 3, 2005
    Assignee: Aventis Pharma S. A.
    Inventors: Patrick Mailliet, Marc Capet, Gilles Tiraboschi, Thomas Caulfield
  • Patent number: 6858603
    Abstract: Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.
    Type: Grant
    Filed: December 16, 2002
    Date of Patent: February 22, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
  • Publication number: 20040235816
    Abstract: Disclosed are azetidine derivatives of formula: 1
    Type: Application
    Filed: June 17, 2004
    Publication date: November 25, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serg Mignani, Augustin Hittinger
  • Publication number: 20040176348
    Abstract: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the gastrointestinal system. Examples of types of disorders that can be treated include neurodegenerative disorders, including central nervous system disorders such as Alzheimer's disease, cognitive disorders, motor disorders such as Parkinson's disease, drug addiction, behavioral disorders and inflammatory disorders within the gastrointestinal system. The compounds can also serve as analgesics in the treatment of acute, chronic or recurrent pain.
    Type: Application
    Filed: March 5, 2003
    Publication date: September 9, 2004
    Applicants: Aventis Pharma S.A., Targacept, Inc.
    Inventors: Jeffrey Daniel Schmitt, Gary Maurice Dull, Arielle Genevois-Borella, Marc Capet, Michel Cheve
  • Patent number: 6767921
    Abstract: The subject of the present invention is the various polymorphic forms I, II, III, IV of benzyl (S,S)-2-(2-acetylsulphanylmethyl-3-benzo[1,3]dioxol-5-ylpropionyl-amino)propionate, hereinafter called Fasidotril, their methods of preparation and novel pharmaceutical compositions containing them.
    Type: Grant
    Filed: March 26, 2003
    Date of Patent: July 27, 2004
    Assignee: Bioproject
    Inventors: Marc Capet, Gérard Coquerel, Denis Danvy, Jeanne-Marie Lecomte, Marie-Noëlle Petit, Jean-Charles Schwartz
  • Publication number: 20030203965
    Abstract: The subject of the present invention is the various polymorphic forms I, II, III, IV of benzyl (S,S)-2-(2-acetylsulphanylmethyl-3-benzo[1,3]dioxol-5-ylpropionyl-amino)propionate, hereinafter called Fasidotril, their methods of preparation and novel pharmaceutical compositions containing them.
    Type: Application
    Filed: March 26, 2003
    Publication date: October 30, 2003
    Inventors: Marc Capet, Gerard Coquerel, Denis Danvy, Jeanne-Marie Lecomte, Marie-Noelle Petit, Jean-Charles Schwartz
  • Publication number: 20030162808
    Abstract: Disclosed are azetidine derivatives of formula: 1
    Type: Application
    Filed: December 16, 2002
    Publication date: August 28, 2003
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
  • Publication number: 20030149072
    Abstract: Substituted arylcycloalkanes, compositions containing them and use thereof. The present invention relates especially to substituted arylcycloalkanes with therapeutic activity, which may be used such as in oncology.
    Type: Application
    Filed: December 4, 2002
    Publication date: August 7, 2003
    Inventors: Patrick Mailliet, Marc Capet, Gilles Tiraboschi, Thomas Caulfield
  • Patent number: 6518264
    Abstract: Disclosed are azetidine derivatives of formula: their optical isomers, their salts, their preparation and medicaments containing them.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: February 11, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Hervé Bouchard, Jean Bouquerel, Marc Capet, Serg Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
  • Publication number: 20020035102
    Abstract: The invention concerns compounds of formula (1) wherein: R represents a chain (A) or (B); R1 is methyl or ethyl; R2 is either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R3 and R4, identical or different, are either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R′ represents a hydrogen atom or a —CO—alk radical, their optical isomers, their salts, their preparation and medicines containing them.
    Type: Application
    Filed: March 9, 2001
    Publication date: March 21, 2002
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Marc Capet, Serge Grisoni, Jean-Luc Malleron, Serge Mignani, Augustin Hittinger
  • Patent number: 6218406
    Abstract: Novel products of formula (I), their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: April 17, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Jean-Dominique Bourzat, Alain Commerçon, Norbert Dereu, Patrick Mailliet, Fabienne Sounigo-Thompson, Jean-Paul Martin, Marc Capet, Michel Cheve
  • Patent number: 6124465
    Abstract: Novel products of formula (I), their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments. ##STR1## In the formula (I), the following substituents are among the preferred: Ar represents a substituted or condensed phenyl radical or a polycyclic or heterocyclic aromatic radical, R represents a radical of general formula --(CH.sub.2).sub.m --X.sub.1 --(CH.sub.2).sub.n --Z in which X.sub.1 =single bond, O, S; m=0, 1; n=0, 1, 2; it being possible for the CH.sub.2 radicals to be substituted; Z represents carboxyl, COOR.sub.6 (R.sub.6 =alkyl), CON(R.sub.7)(R.sub.8) (R.sub.7 =hydrogen or alkyl and R.sub.8 =hydrogen, hydroxyl, arylsulphonyl, heterocyclyl, optionally substituted amino, optionally substituted alkyloxy or optionally substituted alkyl), PO(OR.sub.9).sub.2 (R.sub.9 =hydrogen or alkyl), an --NH--CO--T (T=hydrogen or optionally substituted alkyl) radical, or else--a ##STR2## radical, R.sub.1 and R.sub.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: September 26, 2000
    Assignee: Rhone-Poulenc S.A.
    Inventors: Jean-Dominique Bourzat, Alain Commer.cedilla.on, Norbert Dereu, Patrick Mailliet, Fabienne Sounigo-Thompson, Jean-Paul Martin, Marc Capet, Michel Cheve
  • Patent number: 6013662
    Abstract: Novel products of formula (I), their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments. ##STR1## In the formula (I), the following substituents are among the preferred: Ar represents a substituted or condensed phenyl radical or a polycyclic or heterocyclic aromatic radical, R represents a radical of general formula --(CH.sub.2).sub.m --X.sub.1 --(CH.sub.2).sub.n --Z in which X.sub.1 =single bond, O, S; m=0, 1; n=0, 1, 2; it being possible for the CH.sub.2 radicals to be substituted; Z represents carboxyl, COOR.sub.6 (R.sub.6 =alkyl), CON(R.sub.7)(R.sub.8) (R.sub.7 =hydrogen or alkyl and R.sub.8 =hydrogen, hydroxyl, arylsulphonyl, heterocyclyl, optionally substituted amino, optionally substituted alkyloxy or optionally substituted alkyl), PO(OR.sub.9).sub.2 (R.sub.9 =hydrogen or alkyl), an --NH--CO--T (T=hydrogen or optionally substituted alkyl) radical, or elsea ##STR2## radical, R.sub.1 and R.sub.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: January 11, 2000
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Jean-Dominique Bourzat, Alain Commer.cedilla.on, Norbert Dereu, Patrick Mailliet, Fabienne Sounigo-Thompson, Jean-Paul Martin, Marc Capet, Michel Cheve
  • Patent number: 5716936
    Abstract: Compounds of formula (I), in which R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 are as defined in the specification. The invention also concerns the salts of said compounds, the preparation thereof and the drugs containing same.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: February 10, 1998
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Marc Capet, Marie-Christine Dubroeucq
  • Patent number: 5707991
    Abstract: The present invention relates to derivatives of formula: ##STR1## to their salts, to their preparation and to the medicaments containing them.
    Type: Grant
    Filed: June 28, 1995
    Date of Patent: January 13, 1998
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Marc Capet, Marie-Christine Dubroeucq, Franco Manfre
  • Patent number: 5686622
    Abstract: Thiazolidine derivatives of formula (I), in which R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined in the specification. The invention also concerns the salts of these derivatives, the preparation thereof and drugs containing same.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: November 11, 1997
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Marc Capet, Marie-Christine Dubroeucq, Claude Guyon, Franco Manfre
  • Patent number: 5637602
    Abstract: This invention relates to a compound of formula (I), their salts, the preparation thereof and drugs containing same. The compounds of formula (I) have interesting pharmacological properties. Said compounds have a high affinity for chloecystokinin (CCK) and gastrin receptors and are therefore useful in the treatment and prevention of CCK and gastrin-related disorders affecting the nervous system and gastrointestinal tract.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 10, 1997
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Marc Capet, Marie-Christine Dubroeucq, Franco Manfre, Jean-Paul Martin
  • Patent number: 5624939
    Abstract: Compounds of formula I ##STR1## wherein the substituents are as defined herein, are disclosed as treatments for disorders linked to CCK and gastrin. Processes for preparing the compounds are also taught.
    Type: Grant
    Filed: June 28, 1995
    Date of Patent: April 29, 1997
    Assignee: Rhone-Poulenc Rorer, S.A.
    Inventors: Marc Capet, Marie-Christine Dubroeucq